Osong Public Health and Research Perspectives

Original Articles

Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study: Dong-Hwi Kim, Min-Gyu Yoo, Na-Young Kim, So Young Choi, Minjeong Jang, Misuk An, Se-Jin Jeong, Jungyeon Kim; Osong Public Health Res Perspect. 2024;15(2):137-149. Published online March 28, 2024; DOI: https://doi.org/10.24171/j.phrp.2023.0230

2,149 View
73 Download

Graphical Abstract Abstract PDF Supplementary Material: Objectives
This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older. Using real-world data, the period during which the BN.1 Omicron variant was dominant was compared to the period dominated by the BA.5 variant. Methods: In this retrospective cohort study, data were collected regarding 2,665,281 patients infected with severe acute respiratory syndrome coronavirus 2 between July 24, 2022, and March 31, 2023. Propensity score matching was utilized to match patients who received nirmatrelvir/ ritonavir in a 1:4 ratio between BN.1 and BA.5 variant groups. Multivariable logistic regression analysis was employed to assess the effects of nirmatrelvir/ritonavir within these groups. Results: Compared to the prior period, the efficacy of nirmatrelvir/ritonavir did not significantly differ during the interval of Omicron BN.1 variant dominance in the Republic of Korea. Among patients treated with nirmatrelvir/ritonavir, a significantly lower risk of mortality was observed in the BN.1 group (odds ratio [OR], 0.698; 95% confidence interval [CI], 0.557–0.875) compared to the BA.5 group. However, this treatment did not significantly reduce the risk of severe or critical illness, including death, for those in the BN.1 group (OR, 0.856; 95% CI, 0.728–1.007). Conclusion: Nirmatrelvir/ritonavir has maintained its effectiveness against COVID-19, even with the emergence of the BN.1 Omicron subvariant. Consequently, we strongly recommend the administration of nirmatrelvir/ritonavir to patients exhibiting COVID-19-related symptoms, irrespective of the dominant Omicron variant or their vaccination status, to mitigate disease severity and decrease the risk of mortality.

Household secondary attack rates and risk factors during periods of SARS-CoV-2 Delta and Omicron variant predominance in the Republic of Korea: Jin Lee, Mijeong Ko, Seontae Kim, Dosang Lim, Gemma Park, Sang-Eun Lee; Osong Public Health Res Perspect. 2023;14(4):263-271. Published online August 11, 2023; DOI: https://doi.org/10.24171/j.phrp.2023.0133

3,885 View
160 Download
3 Web of Science
2 Crossref

Objectives
The household secondary attack rate (SAR) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important indicator for community transmission. This study aimed to characterize transmission by comparing household SARs and identifying risk factors during the periods of Delta and Omicron variant predominance in Republic of Korea.
Methods
We defined the period of Delta variant predominance (Delta period) as July 25, 2021 to January 15, 2022, and the period of Omicron variant predominance (Omicron period) as February 7 to September 3, 2022. The number of index cases included was 214,229 for the Delta period and 5,521,393 for the Omicron period. To identify the household SARs and risk factors for each period, logistic regression was performed to determine the adjusted odds ratio (aOR).
Results
The SAR was 35.2% for the Delta period and 43.1% for the Omicron period. The aOR of infection was higher in 2 groups, those aged 0 to 18 years and ≥75 years, compared to those aged 19 to 49 years. Unvaccinated individuals (vs. vaccinated individuals) and individuals experiencing initial infection (vs. individuals experiencing a second or third infection) had an increased risk of infection with SARS-CoV-2.
Conclusion
This study analyzed the household SARs and risk factors. We hope that the results can help develop age-specific immunization plans and responses to reduce the SAR in preparation for emerging infectious diseases or potential new variants of SARS-CoV-2.

Citations

Citations to this article as recorded by

Lower Levels of Household Transmission of SARS-CoV-2 Omicron Variant of Concern vs Wild Type: An Interplay Between Transmissibility and Immune Status
Angelique M A M Winkel, Eva Kozanli, Mildred E Haverkort, Sjoerd M Euser, Judith G C Sluiter-Post, Rob Mariman, Afke Vogelzang, Jordy de Bakker, Coen R Lap, Marianne A van Houten, Dirk Eggink, Steven F L van Lelyveld
The Journal of Infectious Diseases.2025; 231(3): 653. CrossRef
Impact of disease severity, age, sex, comorbidity, and vaccination on secondary attack rates of SARS-CoV-2: a global systematic review and meta-analysis
Dewan Md. Sumsuzzman, Yang Ye, Zhen Wang, Abhishek Pandey, Joanne M. Langley, Alison P. Galvani, Seyed M. Moghadas
BMC Infectious Diseases.2025;[Epub] CrossRef

Increased viral load in patients infected with severe acute respiratory syndrome coronavirus 2 Omicron variant in the Republic of Korea: Jeong-Min Kim, Dongju Kim, Nam-Joo Lee, Sang Hee Woo, Jaehee Lee, Hyeokjin Lee, Ae Kyung Park, Jeong-Ah Kim, Chae Young Lee, Il-Hwan Kim, Cheon Kwon Yoo, Eun-Jin Kim; Osong Public Health Res Perspect. 2023;14(4):272-278. Published online July 27, 2023; DOI: https://doi.org/10.24171/j.phrp.2023.0024

2,832 View
129 Download
2 Web of Science
2 Crossref

Graphical Abstract Abstract PDF Supplementary Material

Objectives
Coronavirus disease 2019 (COVID-19) has been declared a global pandemic owing to the rapid spread of the causative agent, severe acute respiratory syndrome coronavirus 2. Its Delta and Omicron variants are more transmissible and pathogenic than other variants. Some debates have emerged on the mechanism of variants of concern. In the COVID-19 wave that began in December 2021, the Omicron variant, first reported in South Africa, became identifiable in most cases globally. The aim of this study was to provide data to inform effective responses to the transmission of the Omicron variant.
Methods
The Delta variant and the spike protein D614G mutant were compared with the Omicron variant. Viral loads from 5 days after symptom onset were compared using epidemiological data collected at the time of diagnosis.
Results
The Omicron variant exhibited a higher viral load than other variants, resulting in greater transmissibility within 5 days of symptom onset.
Conclusion
Future research should focus on vaccine efficacy against the Omicron variant and compare trends in disease severity associated with its high viral load.

Citations

Citations to this article as recorded by

Replication kinetics and infectivity of SARS-CoV-2 Omicron variant sublineages recovered in the Republic of Korea
Jeong-Min Kim, Dongju Kim, Jee Eun Rhee, Cheon Kwon Yoo, Eun-Jin Kim
Osong Public Health and Research Perspectives.2024; 15(3): 260. CrossRef
Diagnostic Accuracy of the Abbott BinaxNOW COVID‐19 Antigen Card Test, Puerto Rico
Zachary J. Madewell, Chelsea G. Major, Nathan Graff, Cameron Adams, Dania M. Rodriguez, Tatiana Morales, Nicole A. Medina Lopes, Rafael Tosado, Liliana Sánchez‐González, Janice Perez‐Padilla, Hannah R. Volkman, Jorge Bertrán‐Pasarell, Diego Sainz de la Pe
Influenza and Other Respiratory Viruses.2024;[Epub] CrossRef

Results of contact tracing for SARS-CoV-2 Omicron sub-lineages (BA.4, BA.5, BA.2.75) and the household secondary attack risk: Mi Yu, Sang-Eun Lee, Hye Young Lee, Hye-jin Kim, Yeong-Jun Song, Jian Jeong, Ae Kyung Park, Il-Hwan Kim, Eun-jin Kim, Young-Joon Park; Osong Public Health Res Perspect. 2023;14(3):173-179. Published online June 22, 2023; DOI: https://doi.org/10.24171/j.phrp.2022.0285

2,826 View
80 Download
2 Web of Science
2 Crossref

Graphical Abstract Abstract PDF

Objectives
This study aimed to assess the contact tracing outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-lineages BA.4, BA.5, and BA.2.75 within Republic of Korea, and to generate foundational data for responding to future novel variants.
Methods
We conducted investigations and contact tracing for 79 confirmed BA.4 cases, 396 confirmed BA.5 cases, and 152 confirmed BA.2.75 cases. These cases were identified through random sampling of both domestically confirmed and imported cases, with the goal of evaluating the pattern of occurrence and transmissibility.
Results
We detected 79 instances of Omicron sub-lineage BA.4 across a span of 46 days, 396 instances of Omicron sub-lineage BA.5 in 46 days, and 152 instances of Omicron sub-lineage BA.2.75 over 62 days. One patient with severe illness was confirmed among the BA.5 cases; however, there were no reports of severe illness in the confirmed BA.4 and BA.2.75 cases. The secondary attack risk among household contacts were 19.6% for BA.4, 27.8% for BA.5, and 24.3% for BA.2.75. No statistically significant difference was found between the Omicron sub-lineages.
Conclusion
BA.2.75 did not demonstrate a higher tendency for transmissibility, disease severity, or secondary attack risk within households when compared to BA.4 and BA.5. We will continue to monitor major SARS-CoV-2 variants, and we plan to enhance the disease control and response systems.

Citations

Citations to this article as recorded by

Impact of disease severity, age, sex, comorbidity, and vaccination on secondary attack rates of SARS-CoV-2: a global systematic review and meta-analysis
Dewan Md. Sumsuzzman, Yang Ye, Zhen Wang, Abhishek Pandey, Joanne M. Langley, Alison P. Galvani, Seyed M. Moghadas
BMC Infectious Diseases.2025;[Epub] CrossRef
Replication kinetics and infectivity of SARS-CoV-2 Omicron variant sublineages recovered in the Republic of Korea
Jeong-Min Kim, Dongju Kim, Jee Eun Rhee, Cheon Kwon Yoo, Eun-Jin Kim
Osong Public Health and Research Perspectives.2024; 15(3): 260. CrossRef

Brief Report

The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2: Hanul Park, Young Joon Park, Hye Young Lee, Mi Yu, Yeong-Jun Song, Sang Eun Lee, Ji-Joo Lee, Eun-Sol Lee, Yeonjung Kim; Osong Public Health Res Perspect. 2022;13(6):443-447. Published online December 23, 2022; DOI: https://doi.org/10.24171/j.phrp.2022.0262

5,745 View
246 Download
10 Web of Science
13 Crossref

Graphical Abstract Abstract PDF Supplementary Material

Objectives
On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir +ritonavir) asa treatment method that could reduce the risk of hospitalization or death for patients withconfirmed coronavirus disease 2019 (COVID-19).Methods: From February 6, 2022 to April 2, 2022, the incidence of COVID-19 and the effectsof treatment with Paxlovid were analyzed in 2,241 patients and workers at 5 long-term carefacilities during the outbreak of the Omicron variant of severe acute respiratory syndromecoronavirus 2 in South Korea.Results: The rate of severe illness or death in the group given Paxlovid was 51% lower thanthat of the non-Paxlovid group (adjusted risk ratio [aRR], 0.49; 95% confidence interval [CI],0.24−0.98). Compared to unvaccinated patients, patients who had completed 3 doses of thevaccine had a 71% reduced rate of severe illness or death (aRR, 0.29; 95% CI, 0.13−0.64) and a65% reduced death rate (aRR, 0.35; 95% CI, 0.15−0.79).Conclusion: Patients given Paxlovid showed a lower rate of severe illness or death and alower fatality rate than those who did not receive Paxlovid. Patients who received 3 dosesof the vaccine had a lower rate of severe illness or death and a lower fatality rate than theunvaccinated group.

Citations

Citations to this article as recorded by

Tracking SARS-CoV-2 RNA in the air: Lessons from a COVID-19 outbreak in an infirmary unit
Shuk-Ching Wong, Jonathan Hon-Kwan Chen, Pui-Hing Chau, Wai-On Tam, Germaine Kit-Ming Lam, Lithia Lai-Ha Yuen, Wan-Mui Chan, Allen Wing-Ho Chu, Jonathan Daniel Ip, Hoi-Wah Tsoi, Simon Yung-Chun So, Kelvin Hei-Yeung Chiu, Kwok-Yung Yuen, Kelvin Kai-Wang To
American Journal of Infection Control.2025; 53(3): 348. CrossRef
Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis
Meital Zur, Thalia Peselev, Stav Yanko, Victoria Rotshild, Ilan Matok
Antiviral Research.2024; 221: 105768. CrossRef
Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
Sydney Paltra, Tim O. F. Conrad
Advances in Respiratory Medicine.2024; 92(1): 66. CrossRef
Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis
Sien Ombelet, Diego Castanares‐Zapatero, Fabian Desimpel, Frank Hulstaert, Sabine Stordeur, Dominique Roberfroid
Journal of Medical Virology.2024;[Epub] CrossRef
Epidemiological evolution and economic impact of the COVID-19 pandemic in the European Union and worldwide and effects of control strategies on them: An ecological study
J.A. Caylà, J.M. Bellmunt, J.M. Jansà, A. Marco, J.P. Millet
Medicina de Familia. SEMERGEN.2024; 50(6): 102274. CrossRef
Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis
Chienhsiu Huang, Sufang Kuo, Lichen Lin
Tungs' Medical Journal.2024; 18(Suppl 1): S35. CrossRef
Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID‐19 patients with type 2 diabetes: A target trial emulation study
Eric Y. F. Wan, Zoey C. T. Wong, Vincent K. C. Yan, Celine S. L. Chui, Francisco T. T. Lai, Xue Li, Ian C. K. Wong, Esther W. Y. Chan
Diabetes, Obesity and Metabolism.2024; 26(10): 4653. CrossRef
COVID‐19 infection in patients with haematological malignancies: A single‐centre survey in the latest Omicron wave in China
Xiaolu Zhu, Qian Jiang, Jin Lu, Yuqian Sun, Xiaosu Zhao, Shenmiao Yang, Feifei Tang, Wenjing Yu, Ting Zhao, Xiaohong Liu, Jinsong Jia, Wenbing Duan, Lijuan Hu, Jing Wang, Yang Liu, Nan Peng, Xuelin Dou, Rui Ma, Qiang Fu, Huifang Wang, Kaiyan Liu, Xiaojun
British Journal of Haematology.2023; 202(1): 31. CrossRef
The association mental health of adolescents with economic impact during the COVID-19 pandemic: a 2020 Korean nationally representative survey
Hanul Park, Kang-Sook Lee
BMC Public Health.2023;[Epub] CrossRef
Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: An updated meta‐analysis and trial sequential analysis
Haokun Tian, Changsen Yang, Tiangang Song, Kechen Zhou, Lequan Wen, Ye Tian, Lirui Tang, Weikai Xu, Xinyuan Zhang
Reviews in Medical Virology.2023;[Epub] CrossRef
Real-World Effectiveness of Nirmatrelvir-Ritonavir and Its Acceptability in High-Risk COVID-19 Patients
Min-Kyung Kim, Kyung-Shin Lee, Sin Young Ham, Youn Young Choi, Eunyoung Lee, Seungjae Lee, Bora Lee, Jaehyun Jeon, BumSik Chin, Yeonjae Kim, Gayeon Kim, Hee-Chang Jang, Jae-Phil Choi, Sang-Won Park
Journal of Korean Medical Science.2023;[Epub] CrossRef
Effectiveness of Molnupiravir Treatment in Patients with COVID-19 in Korea: A Propensity Score Matched Study
Hye Rim Park, Min-Gyu Yoo, Jong Mu Kim, Soon Jong Bae, Hyungmin Lee, Jungyeon Kim
Infection & Chemotherapy.2023; 55(4): 490. CrossRef
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19
Stefanie Reis, Maria-Inti Metzendorf, Rebecca Kuehn, Maria Popp, Ildiko Gagyor, Peter Kranke, Patrick Meybohm, Nicole Skoetz, Stephanie Weibel
Cochrane Database of Systematic Reviews.2023;[Epub] CrossRef

Original Articles

mRNA vaccine effectiveness against SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant transmission from home care cases to household contacts in South Korea: Hanul Park, Young Joon Park, Sang Eun Lee, Min Jei Lee, Hyungtae Ahn; Osong Public Health Res Perspect. 2022;13(6):435-442. Published online November 28, 2022; DOI: https://doi.org/10.24171/j.phrp.2022.0243

6,369 View
191 Download
2 Web of Science
3 Crossref

Graphical Abstract Abstract PDF Supplementary Material

Objectives
Household contacts of confirmed cases of coronavirus disease 2019 (COVID-19) areexposed to a high risk of viral transmission, and secondary incidence is an important indicatorof community transmission. This study analyzed the secondary attack rate and mRNA vaccineeffectiveness against transmission (VET) for index cases (patients treated at home) confirmedto be infected with the Delta and Omicron variants.Methods: The subjects of the study were 4,450 index cases and 10,382 household contacts.Logistic regression analysis was performed to compare the secondary attack rate byvaccination status, and adjusted relative risk and 95% confidence intervals were identified.Results: The secondary attack rate of the Delta variant was 27.3%, while the secondary attackrate of the Omicron variant was 29.8%. For the Delta variant, groups with less than 90 daysand more than 90 days after 2 doses of mRNA vaccination both showed a VET of 37%. For theOmicron variant, a 64% VET was found among those with less than 90 days after 2 doses ofmRNA vaccination.Conclusion: This study provides useful data on the secondary attack rate and VET of mRNAvaccines for household contacts of COVID-19 cases in South Korea.

Citations

Citations to this article as recorded by

Impact of disease severity, age, sex, comorbidity, and vaccination on secondary attack rates of SARS-CoV-2: a global systematic review and meta-analysis
Dewan Md. Sumsuzzman, Yang Ye, Zhen Wang, Abhishek Pandey, Joanne M. Langley, Alison P. Galvani, Seyed M. Moghadas
BMC Infectious Diseases.2025;[Epub] CrossRef
Child Transmission of SARS-CoV-2 Throughout the Pandemic: An Updated Systematic Review and Meta-Analysis
Eugene Kwon, Gabriel Blank, Samantha Starkey, Cassidy Chapman, Conné Lategan, Hennady Shulha, Vanessa Kitchin, Sarah Silverberg, Laura Sauvé, Manish Sadarangani
Pediatric Infectious Disease Journal.2025;[Epub] CrossRef
Household secondary attack rates and risk factors during periods of SARS-CoV-2 Delta and Omicron variant predominance in the Republic of Korea
Jin Lee, Mijeong Ko, Seontae Kim, Dosang Lim, Gemma Park, Sang-Eun Lee
Osong Public Health and Research Perspectives.2023; 14(4): 263. CrossRef

Investigation of SARS-CoV-2 lineages and mutations circulating in a university-affiliated hospital in South Korea analyzed using Oxford Nanopore MinION sequencing: Hyaekang Kim, Sung Hee Chung, Hyun Soo Kim, Han-Sung Kim, Wonkeun Song, Ki Ho Hong, Jae-Seok Kim; Osong Public Health Res Perspect. 2022;13(5):360-369. Published online October 11, 2022; DOI: https://doi.org/10.24171/j.phrp.2022.0183

4,970 View
93 Download
2 Web of Science
2 Crossref

Abstract PDF Supplementary Material

Objectives
Despite the introduction of vaccines, treatments, and massive diagnostic testing, the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued to overcome barriers that had slowed its previous spread. As the virus evolves towards increasing fitness, it is critical to continue monitoring the occurrence of new mutations that could evade human efforts to control them. Methods: We performed whole-genome sequencing using Oxford Nanopore MinION sequencing on 58 SARS-CoV-2 isolates collected during the ongoing coronavirus disease 2019 pandemic at a tertiary hospital in South Korea and tracked the emergence of mutations responsible for massive spikes in South Korea. Results: The differences among lineages were more pronounced in the spike gene, especially in the receptor-binding domain (RBD), than in other genes. Those RBD mutations could compromise neutralization by antibodies elicited by vaccination or previous infections. We also reported multiple incidences of Omicron variants carrying mutations that could impair the diagnostic sensitivity of reverse transcription-polymerase chain reaction-based testing. Conclusion: These results provide an understanding of the temporal changes of variants and mutations that have been circulating in South Korea and their potential impacts on antigenicity, therapeutics, and diagnostic escape of the virus. We also showed that the utilization of the nanopore sequencing platform and the ARTIC workf low can provide convenient and accurate SARS-CoV-2 genomic surveillance even at a single hospital.

Citations

Citations to this article as recorded by

Understanding large scale sequencing datasets through changes to protein folding
David Shorthouse, Harris Lister, Gemma S Freeman, Benjamin A Hall
Briefings in Functional Genomics.2024; 23(5): 517. CrossRef
Molecular epidemiology of SARS‐CoV‐2 in Mongolia, first experience with nanopore sequencing in lower‐ and middle‐income countries setting
Munkhtuya Erendereg, Suvd Tumurbaatar, Otgonjargal Byambaa, Gerelmaa Enebish, Natsagdorj Burged, Tungalag Khurelsukh, Nomin‐Erdene Baatar, Badmaarag Munkhjin, Jargaltulga Ulziijargal, Anuujin Gantumur, Oyunbaatar Altanbayar, Ochbadrakh Batjargal, Delgermu
Immunity, Inflammation and Disease.2023;[Epub] CrossRef

Review Article

Review of the early reports of the epidemiological characteristics of the B.1.1.7 variant of SARS-CoV-2 and its spread worldwide: Yeonju Kim, Eun-Jin Kim, Sang-Won Lee, Donghyok Kwon; Osong Public Health Res Perspect. 2021;12(3):139-148. Published online June 24, 2021; DOI: https://doi.org/10.24171/j.phrp.2021.0037

8,375 View
178 Download
8 Web of Science
9 Crossref

Abstract PDF

The variant B.1.1.7 of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the RNA virus causing the pandemic more than a year worldwide, was reported from United Kingdom (UK) in late December 2020. It was reported that mortality increases by 65% and transmissibility increases by 70%, which may result in an increase of reproduction number to 1.13−1.55 from 0.75−0.85. To analyze the global increasing trend of the variant B.1.1.7, we extracted results of B.1.1.7 from GISAID on May 11 and May 12, 2021, and conducted a doseresponse regression. It took 47 days to reach 20% and 121 days to reach 50% among the sequence submitted from UK. In Korea, cases of B.1.1.7 have increased since the first report of three cases on December 28, 2020. Positive rate of B.1.1.7 in Korea was 21.6% in the week from May 9 to May 15, 2021. Detection rate of the variants is expected to increase further and new variants of SARS-CoV-2 are emerging, so a close monitoring and control would be maintained for months.

Citations

Citations to this article as recorded by

Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
Ahmed I. Abulsoud, Hussein M. El-Husseiny, Ahmed A. El-Husseiny, Hesham A. El-Mahdy, Ahmed Ismail, Samy Y. Elkhawaga, Emad Gamil Khidr, Doaa Fathi, Eman A. Mady, Agnieszka Najda, Mohammad Algahtani, Abdulrahman Theyab, Khalaf F. Alsharif, Ashraf Albrakati
Biomedicine & Pharmacotherapy.2023; 157: 113977. CrossRef
Structural implications of SARS-CoV-2 Surface Glycoprotein N501Y mutation within receptor-binding domain [499-505] – computational analysis of the most frequent Asn501 polar uncharged amino acid mutations
Done Stojanov
Biotechnology & Biotechnological Equipment.2023;[Epub] CrossRef
Molecular and Clinical Epidemiology of SARS-CoV-2 Infection among Vaccinated and Unvaccinated Individuals in a Large Healthcare Organization from New Jersey
José R. Mediavilla, Tara Lozy, Annie Lee, Justine Kim, Veronica W. Kan, Elizabeth Titova, Ashish Amin, Michael C. Zody, André Corvelo, Dayna M. Oschwald, Amy Baldwin, Samantha Fennessey, Jerry M. Zuckerman, Thomas Kirn, Liang Chen, Yanan Zhao, Kar Fai Cho
Viruses.2023; 15(8): 1699. CrossRef
Incidence Evaluation of SARS-CoV-2 Variants in the Ulsan Area, Korea, Using PowerChek SARS-CoV-2 S-gene Mutation Detection Kit: A Pilot Study
Sang Hyuk Park, Hyun-Ki Kim, Hang Kang, Jung Heon Kim, Jaeseung Lee, Ji-Hun Lim, Seon-Ho Lee, Joseph Jeong
Annals of Laboratory Medicine.2022; 42(3): 363. CrossRef
Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
Reem Hoteit, Hadi M. Yassine
Vaccines.2022; 10(6): 919. CrossRef
Virtual recruitment and participant engagement for substance use research during a pandemic
Carolin C. Hoeflich, Anna Wang, Ayodeji Otufowora, Linda B. Cottler, Catherine W. Striley
Current Opinion in Psychiatry.2022; 35(4): 252. CrossRef
Display of receptor-binding domain of SARS-CoV-2 Spike protein variants on the Saccharomyces cerevisiae cell surface
Hongguan Xing, Liyan Zhu, Pingping Wang, Guoping Zhao, Zhihua Zhou, Yi Yang, Hong Zou, Xing Yan
Frontiers in Immunology.2022;[Epub] CrossRef
Mutations in SARS-CoV-2 nucleocapsid in variants of concern impair the sensitivity of SARS-CoV-2 detection by rapid antigen tests
Ibrahim T. Hagag, Krzysztof Pyrc, Saskia Weber, Anne Balkema-Buschmann, Martin H. Groschup, Markus Keller
Frontiers in Virology.2022;[Epub] CrossRef
The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern
Lixin Lin, Ying Liu, Xiujuan Tang, Daihai He
Frontiers in Public Health.2021;[Epub] CrossRef

Brief Reports

Occurrence of Norovirus GII.4 Sydney Variant-related Outbreaks in Korea: Sunyoung Jung, Bo-Mi Hwang, Hyun Ju Jeong, Gyung Tae Chung, Cheon-Kwon Yoo, Yeon-Ho Kang, Deog-Yong Lee; Osong Public Health Res Perspect. 2015;6(5):322-326. Published online October 31, 2015; DOI: https://doi.org/10.1016/j.phrp.2015.10.004

4,193 View
26 Download
8 Crossref

Abstract PDF

Human noroviruses are major causative agents of food and waterborne outbreaks of nonbacterial acute gastroenteritis. In this study, we report the epidemiological features of three outbreak cases of norovirus in Korea, and we describe the clinical symptoms and distribution of the causative genotypes. The incidence rates of the three outbreaks were 16.24% (326/2,007), 4.1% (27/656), and 16.8% (36/214), respectively. The patients in these three outbreaks were affected by acute gastroenteritis. These schools were provided unheated food from the same manufacturing company. Two genotypes (GII.3 and GII.4) of the norovirus were detected in these cases. Among them, major causative strains of GII.4 (Hu-jeju-47-2007KR-like) were identified in patients, food handlers, and groundwater from the manufacturing company of the unheated food. In the GII.4 (Hu-jeju-47-2007KR-like) strain of the norovirus, the nucleotide sequences were identical and identified as the GII.4 Sydney variant. Our data suggests that the combined epidemiological and laboratory results were closely related, and the causative pathogen was the GII.4 Sydney variant strain from contaminated groundwater.

Citations

Citations to this article as recorded by

A systematic review and meta-analysis indicates a substantial burden of human noroviruses in shellfish worldwide, with GII.4 and GII.2 being the predominant genotypes
Yijing Li, Liang Xue, Junshan Gao, Weicheng Cai, Zilei Zhang, Luobing Meng, Shuidi Miao, Xiaojing Hong, Mingfang Xu, Qingping Wu, Jumei Zhang
Food Microbiology.2023; 109: 104140. CrossRef
Molecular epidemiology of norovirus infections in children with acute gastroenteritis in 2017–2019 in Tianjin, China
Yulian Fang, Yanzhi Zhang, Hong Wang, Ouyan Shi, Wei Wang, Mengzhu Hou, Lu Wang, Jinying Wu, Yu Zhao
Journal of Medical Virology.2022; 94(2): 616. CrossRef
Assessment of potential infectivity of human norovirus in the traditional Korean salted clam product “Jogaejeotgal” by floating electrode-dielectric barrier discharge plasma
Eun Bi Jeon, Man-Seok Choi, Ji Yoon Kim, Eun Ha Choi, Jun Sup Lim, Jinsung Choi, Kwang Soo Ha, Ji Young Kwon, Sang Hyeon Jeong, Shin Young Park
Food Research International.2021; 141: 110107. CrossRef
Characterizing the effects of thermal treatment on human norovirus GII.4 viability using propidium monoazide combined with RT-qPCR and quality assessments in mussels
Eun Bi Jeon, Man-Seok Choi, Ji Yoon Kim, Kwang Soo Ha, Ji Young Kwon, Sung Hyeon Jeong, Hee Jung Lee, Yeoun Joong Jung, Ji-Hyoung Ha, Shin Young Park
Food Control.2020; 109: 106954. CrossRef
Molecular epidemiology of genogroup II norovirus infections in acute gastroenteritis patients during 2014–2016 in Pudong New Area, Shanghai, China
Caoyi Xue, Lifeng Pan, Weiping Zhu, Yuanping Wang, Huiqin Fu, Chang Cui, Lan Lu, Sun Qiao, Biao Xu
Gut Pathogens.2018;[Epub] CrossRef
Review: Epidemiological evidence of groundwater contribution to global enteric disease, 1948–2015
Heather M. Murphy, Morgan D. Prioleau, Mark A. Borchardt, Paul D. Hynds
Hydrogeology Journal.2017; 25(4): 981. CrossRef
Change in Concentrations of Human Norovirus and Male-Specific Coliphage under Various Temperatures, Salinities, and pH Levels in Seawater
Poong Ho Kim, Yong Soo Park, Kunbawui Park, Ji Young Kwon, Hong Sik Yu, Hee Jung Lee, Ji Hoe Kim, Tae Seek Lee
Korean Journal of Fisheries and Aquatic Sciences.2016; 49(4): 454. CrossRef
Norovirus outbreaks occurred in different settings in the Republic of Korea
Hae-Wol Cho, Chaeshin Chu
Osong Public Health and Research Perspectives.2015; 6(5): 281. CrossRef

Epidemics of Norovirus GII.4 Variant in Outbreak Cases in Korea, 2004–2012: Sunyoung Jung, Hyun Ju Jeong, Bo-Mi Hwang, Cheon-Kwon Yoo, Gyung Tae Chung, Hyesook Jeong, Yeon-Ho Kang, Deog-Yong Lee; Osong Public Health Res Perspect. 2015;6(5):318-321. Published online October 31, 2015; DOI: https://doi.org/10.1016/j.phrp.2015.10.002

4,229 View
31 Download
2 Crossref

Abstract PDF

Norovirus GII.4 is recognized as a worldwide cause of nonbacterial outbreaks. In particular, the GII.4 variant occurs every 2–3 years according to antigenic variation. The aim of our study was to identify GII.4 variants in outbreaks in Korea during 2004–2012. Partial VP1 sequence of norovirus GII.4-related outbreaks during 2004–2012 was analyzed. The partial VP1 sequence was detected with reverse transcription-polymerase chain reaction, seminested polymerase chain reaction, and nucleotide sequence of 312-314 base pairs for phylogenetic comparison. Nine variants emerged in outbreaks, with the Sydney variant showing predominance recently. This predominance may persist for at least 3 years, although new variants may appear in Korea.

Citations

Citations to this article as recorded by

Trends for Syndromic Surveillance of Norovirus in Emergency Department Data Based on Chief Complaints
Soyeoun Kim, Sohee Kim, Bo Youl Choi, Boyoung Park
The Journal of Infectious Diseases.2024; 230(1): 103. CrossRef
Genotypic and Epidemiological Trends of Acute Gastroenteritis Associated with Noroviruses in China from 2006 to 2016
Shu-Wen Qin, Ta-Chien Chan, Jian Cai, Na Zhao, Zi-Ping Miao, Yi-Juan Chen, She-Lan Liu
International Journal of Environmental Research an.2017; 14(11): 1341. CrossRef

Review Article

Prion Diseases as Transmissible Zoonotic Diseases: Jeongmin Lee, Su Yeon Kim, Kyu Jam Hwang, Young Ran Ju, Hee-Jong Woo; Osong Public Health Res Perspect. 2013;4(1):57-66. Published online February 28, 2013; DOI: https://doi.org/10.1016/j.phrp.2012.12.008

4,575 View
30 Download
27 Crossref

Abstract PDF

Prion diseases, also called transmissible spongiform encephalopathies (TSEs), lead to neurological dysfunction in animals and are fatal. Infectious prion proteins are causative agents of many mammalian TSEs, including scrapie (in sheep), chronic wasting disease (in deer and elk), bovine spongiform encephalopathy (BSE; in cattle), and Creutzfeldt–Jakob disease (CJD; in humans). BSE, better known as mad cow disease, is among the many recently discovered zoonotic diseases. BSE cases were first reported in the United Kingdom in 1986. Variant CJD (vCJD) is a disease that was first detected in 1996, which affects humans and is linked to the BSE epidemic in cattle. vCJD is presumed to be caused by consumption of contaminated meat and other food products derived from affected cattle. The BSE epidemic peaked in 1992 and decreased thereafter; this decline is continuing sharply owing to intensive surveillance and screening programs in the Western world. However, there are still new outbreaks and/or progression of prion diseases, including atypical BSE, and iatrogenic CJD and vCJD via organ transplantation and blood transfusion. This paper summarizes studies on prions, particularly on prion molecular mechanisms, BSE, vCJD, and diagnostic procedures. Risk perception and communication policies of the European Union for the prevention of prion diseases are also addressed to provide recommendations for appropriate government policies in Korea.

Citations

Citations to this article as recorded by

CRISPR/Cas9-editing of PRNP in Alpine goats
Aurélie Allais-Bonnet, Christophe Richard, Marjolaine André, Valérie Gelin, Marie-Christine Deloche, Aurore Lamadon, Gwendoline Morin, Béatrice Mandon-Pépin, Eugénie Canon, Dominique Thépot, Johann Laubier, Katayoun Moazami-Goudarzi, Ludivine Laffont, Oli
Veterinary Research.2025;[Epub] CrossRef
New Food Ingredients: The Challenge of Potential New Pathogens and Spoilage Issues
Michael Leonidas Chikindas, Donald W. Schaffner, Svetoslav Dimitrov Todorov
Molecular Nutrition & Food Research.2025;[Epub] CrossRef
Single nucleotide polymorphisms (SNPs) in the open reading frame (ORF) of prion protein gene (PRNP) in Nigerian livestock species
Adeniyi C. Adeola, Semiu F. Bello, Abdussamad M. Abdussamad, Rahamon A. M. Adedokun, Sunday C. Olaogun, Nasiru Abdullahi, Akanbi I. Mark, Anyebe B. Onoja, Oscar J. Sanke, Godwin F. Mangbon, Jebi Ibrahim, Philip M. Dawuda, Adebowale E. Salako, Samia Kdidi,
BMC Genomics.2024;[Epub] CrossRef
Evaluating the inter-species transmission risk of amyloid beta peptide aggregates via ingestion
Joshua Raine, Nicholas Tolwinski, Jan Gruber, Ajay S. Mathuru
Alzheimer's Research & Therapy.2024;[Epub] CrossRef
Morzeddhu: A Unique Example of a Traditional and Sustainable Typical Dish from Catanzaro
Stefano Alcaro, Roberta Rocca, Maria Grazia Rotundo, Francesco Bianco, Luigi Scordamaglia
Foods.2024; 13(12): 1810. CrossRef
Responsible innovation: Mitigating the food safety aspects of cultured meat production
Louise Manning
Journal of Food Science.2024; 89(8): 4638. CrossRef
Countering Zoonotic Diseases: Current Scenario and Advances in Diagnostics, Monitoring, Prophylaxis and Therapeutic Strategies
Saurabh Gupta, Rasanpreet Kaur, Jagdip Singh Sohal, Shoor Vir Singh, Kaushik Das, Manish Kumar Sharma, Jitendra Singh, Shalini Sharma, Kuldeep Dhama
Archives of Medical Research.2024; 55(6): 103037. CrossRef
Scrapie-associated polymorphisms of the prion protein gene (PRNP) in Nigerian native goats
Adeniyi C. Adeola, Semiu F. Bello, Abdussamad M. Abdussamad, Akanbi I. Mark, Oscar J. Sanke, Anyebe B. Onoja, Lotanna M. Nneji, Nasiru Abdullahi, Sunday C. Olaogun, Lawal D. Rogo, Godwin F. Mangbon, Shamsudeen L. Pedro, Manasseh P. Hiinan, Muhammad M. Muk
Gene.2023; 855: 147121. CrossRef
Infections and immunity: associations with obesity and related metabolic disorders
Amitabha Ray, Melissa J. L. Bonorden, Rajashree Pandit, Katai J. Nkhata, Anupam Bishayee
Journal of Pathology and Translational Medicine.2023; 57(1): 28. CrossRef
The concept of one health applied to the problem of zoonotic diseases
Mohamed N. F. Shaheen
Reviews in Medical Virology.2022;[Epub] CrossRef
Exploring the prospects of the fifth quarter in the 21st century
Philip O. Soladoye, Manuel Juárez, Mario Estévez, Yu Fu, Carlos Álvarez
Comprehensive Reviews in Food Science and Food Saf.2022; 21(2): 1439. CrossRef
Gene-Edited Cell Models to Study Chronic Wasting Disease
Simrika Thapa, Cristobal Marrero Winkens, Waqas Tahir, Maria I. Arifin, Sabine Gilch, Hermann M. Schatzl
Viruses.2022; 14(3): 609. CrossRef
Optimization Based Modeling for the Food Supply Chain's Resilience to Outbreaks
Emma Moynihan, Charalampos Avraam, Sauleh Siddiqui, Roni Neff
Frontiers in Sustainable Food Systems.2022;[Epub] CrossRef
Eco-Friendly Alternative Disposal through the Pyrolysis Process of Meat and Bone Meal
Anca Maria Zaharioiu, Claudia Şandru, Eusebiu Ilarian Ionete, Florian Marin, Roxana Elena Ionete, Amalia Soare, Marius Constantinescu, Felicia Bucura, Violeta-Carolina Niculescu
Materials.2022; 15(19): 6593. CrossRef
Safety of Alternative Proteins: Technological, Environmental and Regulatory Aspects of Cultured Meat, Plant-Based Meat, Insect Protein and Single-Cell Protein
Joshua Hadi, Gale Brightwell
Foods.2021; 10(6): 1226. CrossRef
“It’s important to know about this” - risk communication and the impacts of chronic wasting disease on indigenous food systems in Western Canada
Brenda Parlee, Kevin Ahkimnachie, Hannah Cunningham, Magdalena Jordan, Ellen Goddard
Environmental Science & Policy.2021; 123: 190. CrossRef
PMCA Applications for Prion Detection in Peripheral Tissues of Patients with Variant Creutzfeldt-Jakob Disease
Giorgio Giaccone, Fabio Moda
Biomolecules.2020; 10(3): 405. CrossRef
Riesgos y complicaciones clínicas asociadas con los injertos de origen bovino
Ángel Emmanuel Rodríguez, Hessam Nowzari
Revista de la Asociación Dental Mexicana.2020; 77(2): 108. CrossRef
Comparative proteomic analysis of mitochondrial proteins from maize CMS‐C sterile, maintainer and restorer anthers
Huaisheng Zhang, Bin Wang, Bing Li, Yanan Lin, Huili Yang, Dong Ding, Yadong Xue, Jihua Tang
The Plant Genome.2020;[Epub] CrossRef
The Causal Relationship between Eating Animals and Viral Epidemics
Bhaskara L. Reddy, Milton H., Jr. Saier
Microbial Physiology.2020; 30(1-6): 2. CrossRef
Problems with precaution: the transfusion medicine experience
Kumanan Wilson, Katherine M. Atkinson, Dean A. Fergusson, Adalsteinn Brown, Alan Forster, Malia S. Q. Murphy, Alan T. Tinmouth, Jennifer Keelan
Journal of Risk Research.2019; 22(2): 137. CrossRef
Valuing the investigation of Prion diseases in Ethiopia
Teferedegn EY, Tesfaye D, Un C
International Journal of Agricultural Science and .2019; : 001. CrossRef
Neuroradiology of human prion diseases, diagnosis and differential diagnosis
Simona Gaudino, Emma Gangemi, Raffaella Colantonio, Annibale Botto, Emanuela Ruberto, Rosalinda Calandrelli, Matia Martucci, Maria Gabriella Vita, Carlo Masullo, Alfonso Cerase, Cesare Colosimo
La radiologia medica.2017; 122(5): 369. CrossRef
The Risk of Prion Infection through Bovine Grafting Materials
Yeoungsug Kim, Angel Emmanuel Rodriguez, Hessam Nowzari
Clinical Implant Dentistry and Related Research.2016; 18(6): 1095. CrossRef
Review: Laboratory diagnosis and surveillance of Creutzfeldt-Jakob disease
Jeongmin Lee, Jae Wook Hyeon, Su Yeon Kim, Kyu-Jam Hwang, Young Ran Ju, Chongsuk Ryou
Journal of Medical Virology.2015; 87(1): 175. CrossRef
Avaliação epidemiológica dos óbitos por doenças priônicas no Brasil sob o enfoque da biossegurança
Camila Abdalla de Oliveira Cardoso, Marli Brito Moreira de Albuquerque Navarro, Bernardo Elias Correa Soares, Telma Abdalla de Oliveira Cardoso
Cadernos Saúde Coletiva.2015; 23(1): 2. CrossRef
Molecular cloning and sequence analysis of prion protein gene in Xiji donkey in China
Zhuming Zhang, Renli Wang, Lihua Xu, Fangzhong Yuan, Xiangmei Zhou, Lifeng Yang, Xiaomin Yin, Binrui Xu, Deming Zhao
Gene.2013; 529(2): 345. CrossRef

First
Prev
Page of 1
Next
Last

Search